Lb Pharmaceuticals (LBRX) Capital Expenditures (2024 - 2026)

Lb Pharmaceuticals' Capital Expenditures history runs 3 years deep, the most recent figure standing at $32000.0 for Q1 2026.

• On a quarterly basis, Capital Expenditures rose 52.38% year-over-year to $32000.0 in Q1 2026; TTM through Mar 2026 was $331000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $52000.0, down 93.24% from the prior year.
• Capital Expenditures slipped to $32000.0 in Q1 2026 per LBRX's latest filing, from $40000.0 in the prior quarter.
• Across five years, Capital Expenditures topped out at $238000.0 in Q4 2024 and bottomed at $21000.0 in Q1 2025.
• The 3-year median for Capital Expenditures is $36000.0 (2025), against an average of $82750.0.
• Across the five-year window, Capital Expenditures plunged 83.19% in 2025 and soared 52.38% in 2026, its largest moves.
• Year by year, Capital Expenditures stood at $238000.0 in 2024, then sank by 83.19% to $40000.0 in 2025, then dropped by 20.0% to $32000.0 in 2026.
• Per Business Quant, the three latest LBRX Capital Expenditures figures stand at $32000.0 (Q1 2026), $40000.0 (Q4 2025), and $21000.0 (Q1 2025).